Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain
IntroductionPre-exposure prophylaxis (PrEP) has become a useful tool to reduce the transmission of human immunodeficiency virus (HIV) in key populations. In this article we assessed the effectiveness, safety, adherence, sexually transmitted infections (STIs) dynamics, and frequency of anal dysplasia...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1005622/full |
| _version_ | 1797989792137347072 |
|---|---|
| author | Alexandre Pérez-González Alexandre Pérez-González Marta Represa Pep Coll Pep Coll Carmen Potel Silvia Rodríguez-Rivero Erene V. Flores Claudia Vázquez-Estévez Antonio Ocampo Guillermo Pousada Eva Poveda |
| author_facet | Alexandre Pérez-González Alexandre Pérez-González Marta Represa Pep Coll Pep Coll Carmen Potel Silvia Rodríguez-Rivero Erene V. Flores Claudia Vázquez-Estévez Antonio Ocampo Guillermo Pousada Eva Poveda |
| author_sort | Alexandre Pérez-González |
| collection | DOAJ |
| description | IntroductionPre-exposure prophylaxis (PrEP) has become a useful tool to reduce the transmission of human immunodeficiency virus (HIV) in key populations. In this article we assessed the effectiveness, safety, adherence, sexually transmitted infections (STIs) dynamics, and frequency of anal dysplasia among a real-life cohort of PrEP users in Northwest Spain.MethodsA retrospective cohort study was undertaken in the Alvaro-Cunqueiro Hospital, Vigo which included every individual who started daily emtricitabine/tenofovir-disoproxil-fumarate (FTC/TDF) between November-2019 and October-2021. Clinical and epidemiological data were obtained from the patient's medical records. The effectiveness and safety of FTC/TDF were assessed by HIV serology and renal function monitoring every 3 months. Anal, urethral, and oropharyngeal exudates were collected quarterly after the baseline visit.ResultsA total of 126 individuals were considered eligible, most of the participants had previously been diagnosed with a STI (60.3%), 22% had consumed recreational drugs in the year prior, and 13% had engaged in chemsex. At the end of the follow-up, no cases of HIV infection were detected; 3 patients had discontinued FTC/TDF because of side effects but none of them had presented renal toxicity. In addition, the diagnosis of STIs during the follow-up was common (100 cases in 54 patients). Moreover, engagement in chemsex was more common within this latter group (22 vs. 6%, p = 0.013). Among the study population included in the anal screening programme, the frequency of dysplasia was 9%.ConclusionsFTC/TDF was effective, safe, and tolerable in a real-life cohort; adherence remained high throughout the study period (79%). However, a high number of STIs were diagnosed, especially among patients who engaged in chemsex. |
| first_indexed | 2024-04-11T08:25:05Z |
| format | Article |
| id | doaj.art-cf1cef461c2d40b7a0f28d99df36f257 |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-11T08:25:05Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-cf1cef461c2d40b7a0f28d99df36f2572022-12-22T04:34:47ZengFrontiers Media S.A.Frontiers in Public Health2296-25652022-10-011010.3389/fpubh.2022.10056221005622Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest SpainAlexandre Pérez-González0Alexandre Pérez-González1Marta Represa2Pep Coll3Pep Coll4Carmen Potel5Silvia Rodríguez-Rivero6Erene V. Flores7Claudia Vázquez-Estévez8Antonio Ocampo9Guillermo Pousada10Eva Poveda11Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, SpainInfectious Diseases Unit, Internal Medicine Department, Complexo Hospitalario Universitario de Vigo, Vigo, SpainInfectious Diseases Unit, Internal Medicine Department, Complexo Hospitalario Universitario de Vigo, Vigo, SpainIrsiCaixa AIDS Research Institute, Barcelona, SpainInfectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Barcelona, SpainMicrobiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, SpainAnal Dysplasia Unit, General Surgery Department, Complexo Hospitalario Universitario de Vigo, Vigo, SpainAnal Dysplasia Unit, General Surgery Department, Complexo Hospitalario Universitario de Vigo, Vigo, SpainInfectious Diseases Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, SpainInfectious Diseases Unit, Internal Medicine Department, Complexo Hospitalario Universitario de Vigo, Vigo, SpainInfectious Diseases Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, SpainGroup of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur), Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, SpainIntroductionPre-exposure prophylaxis (PrEP) has become a useful tool to reduce the transmission of human immunodeficiency virus (HIV) in key populations. In this article we assessed the effectiveness, safety, adherence, sexually transmitted infections (STIs) dynamics, and frequency of anal dysplasia among a real-life cohort of PrEP users in Northwest Spain.MethodsA retrospective cohort study was undertaken in the Alvaro-Cunqueiro Hospital, Vigo which included every individual who started daily emtricitabine/tenofovir-disoproxil-fumarate (FTC/TDF) between November-2019 and October-2021. Clinical and epidemiological data were obtained from the patient's medical records. The effectiveness and safety of FTC/TDF were assessed by HIV serology and renal function monitoring every 3 months. Anal, urethral, and oropharyngeal exudates were collected quarterly after the baseline visit.ResultsA total of 126 individuals were considered eligible, most of the participants had previously been diagnosed with a STI (60.3%), 22% had consumed recreational drugs in the year prior, and 13% had engaged in chemsex. At the end of the follow-up, no cases of HIV infection were detected; 3 patients had discontinued FTC/TDF because of side effects but none of them had presented renal toxicity. In addition, the diagnosis of STIs during the follow-up was common (100 cases in 54 patients). Moreover, engagement in chemsex was more common within this latter group (22 vs. 6%, p = 0.013). Among the study population included in the anal screening programme, the frequency of dysplasia was 9%.ConclusionsFTC/TDF was effective, safe, and tolerable in a real-life cohort; adherence remained high throughout the study period (79%). However, a high number of STIs were diagnosed, especially among patients who engaged in chemsex.https://www.frontiersin.org/articles/10.3389/fpubh.2022.1005622/fullHIVpre-exposure prophylaxis (PrEP)sexually transmitted infectionsChlamydia trachomatisNeisseria gonorrhoeaehuman papillomavirus (HPV) |
| spellingShingle | Alexandre Pérez-González Alexandre Pérez-González Marta Represa Pep Coll Pep Coll Carmen Potel Silvia Rodríguez-Rivero Erene V. Flores Claudia Vázquez-Estévez Antonio Ocampo Guillermo Pousada Eva Poveda Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain Frontiers in Public Health HIV pre-exposure prophylaxis (PrEP) sexually transmitted infections Chlamydia trachomatis Neisseria gonorrhoeae human papillomavirus (HPV) |
| title | Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain |
| title_full | Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain |
| title_fullStr | Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain |
| title_full_unstemmed | Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain |
| title_short | Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain |
| title_sort | real life cohort experience after implementing hiv pre exposure prophylaxis for one year in northwest spain |
| topic | HIV pre-exposure prophylaxis (PrEP) sexually transmitted infections Chlamydia trachomatis Neisseria gonorrhoeae human papillomavirus (HPV) |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1005622/full |
| work_keys_str_mv | AT alexandreperezgonzalez reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT alexandreperezgonzalez reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT martarepresa reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT pepcoll reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT pepcoll reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT carmenpotel reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT silviarodriguezrivero reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT erenevflores reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT claudiavazquezestevez reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT antonioocampo reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT guillermopousada reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain AT evapoveda reallifecohortexperienceafterimplementinghivpreexposureprophylaxisforoneyearinnorthwestspain |